Trial reportJAMA oncology2017
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial.
Trial report in JAMA oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Prospective Study of Annual Whole-Body Magnetic Resonance Imaging as Part of a Multimodality Screening Program for Individuals With Li-Fraumeni Syndrome.JCO precision oncology · 2025Article
- A profile of lung cancer in the young population with a highlight on the Indian perspective.Frontiers in oncology · 2025Review
- Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.Blood cancer discovery · 2024Article
- Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance.Molecular cancer · 2024Article
- Article
- Assessment of medical knowledge toward genetic testing for individuals with hereditary breast and ovarian cancer syndrome in Brazil.Preventive medicine reports · 2023Article
- Rate of Pathogenic Germline Variants in Patients With Lung Cancer.JCO precision oncology · 2023Review
- The global burden of lung cancer: current status and future trends.Nature reviews. Clinical oncology · 2023Review
- Lung cancer is also a hereditary disease.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Lung Cancer as a Subsequent Malignant Neoplasm in Survivors of Childhood Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Blood functional assay for rapid clinical interpretation of germlineJournal of medical genetics · 2021Article
- Identification of theJCO global oncology · 2021Article
- Lung Cancer in Li-Fraumeni Syndrome.JCO precision oncology · 2021Article
- Epidemiology and clinicopathological features of lung cancer in patients with prior history of breast cancer.SAGE open medicine · 2021Review
- Prevalence of the BrazilianFrontiers in genetics · 2021Article
- GermlineCancers · 2020Review
- Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes.European journal of human genetics : EJHG · 2020Article
- Whole-body MRI within a surveillance program for carriers with clinically actionable germlineHereditary cancer in clinical practice · 2020Article
- Inherited lung cancer: a review.Ecancermedicalscience · 2020Review
- Molecular diagnosis and clinical outcome of a lung cancer patient withAmerican journal of translational research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.